Employees: 2,131
Size Jiangsu Lianhuan Pharmaceutical (600513.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $496M, the 3718th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.82 on 18 Nov 2026.
Performance Over six months the shares fell 41.0%, against -12.8% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 14.3% over the last twelve months (peer median +9.8%); the operating margin is -0.3% (peer median 10.9%).
Valuation It trades at 1.8× enterprise value to sales against a peer median of 4.0× (3rd cheapest of 20).
Capital Return on invested capital runs 3.9 points below its cost of capital (5.6% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥2.96B | CN¥2.70B | CN¥2.14B | CN¥2.15B | CN¥1.94B |
| Revenue growth | — | +26% | -1% | +11% | — |
| Gross profit | CN¥940M | CN¥888M | CN¥1.02B | CN¥999M | CN¥1.01B |
| EBITDA | n/a | CN¥115M | CN¥182M | CN¥235M | CN¥244M |
| Net income | -CN¥48.6M | -CN¥98.3M | CN¥84.2M | CN¥135M | CN¥141M |
| Free cash flow | -CN¥181M | -CN¥286M | -CN¥174M | -CN¥40.0M | -CN¥93.1M |
| Capital expenditure | CN¥255M | CN¥271M | CN¥185M | CN¥201M | CN¥221M |
| Total debt | CN¥1.90B | CN¥1.72B | CN¥942M | CN¥788M | CN¥740M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 600513.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.6% | -0.8% | 2nd lowest of 21 |
| 6-month return | -41.0% | -12.8% | lowest of 21 |
| Distance from 52-week high | -63.4% | -34.8% | lowest of 21 |
| Revenue growth (TTM) | +14.3% | +9.8% | 8th highest of 20 |
| Operating margin | -0.3% | 10.9% | 8th lowest of 20 |
| EV / Sales | 1.8× | 4.0× | 3rd cheapest of 20 |
| ROIC minus cost of capital | -3.9 pp | -2.4 pp | 7th lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Jiangsu Lianhuan Pharmaceutical 600513.SS | China | $496M | -41% | +14% | 0% | 1.8× | n/a | n/a |
| Alpha Teknova TKNO | United States | $496M | +113% | +15% | -32% | 11.0× | n/a | n/a |
| Daewoong 003090.KS | South Korea | $495M | -28% | +6% | 11% | 0.9× | n/a | n/a |
| Henan Taloph Pharmaceutical Stock 600222.SS | China | $497M | -21% | -5% | 7% | 2.5× | 16.7% | +4.4% |
| Aarti Drugs AARTIDRUGS.NS | India | $494M | +34% | +15% | 11% | 1.8× | 22.1% | +3.5% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Gyre Therapeutics GYRE | United States | $500M | -28% | +14% | -18% | 4.0× | n/a | n/a |
| Shanghai Xiao Fang Pharmaceutical 603207.SS | China | $503M | -17% | +10% | 39% | 4.8× | -5.4% | +7.6% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Gujarat Themis Biosyn GUJTHEM.NS | India | $505M | +2% | +18% | 39% | 27.2× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Indaptus Therapeutics INDP | United States | $505M | +147% | n/a | n/a | n/a | n/a | n/a |
| Egetis Therapeutics EGTX.ST | Sweden | $509M | +76% | +27% | -645% | 71.0× | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Xizang Weixinkang Pharmaceutical 603676.SS | China | $513M | -22% | -8% | 16% | 2.3× | -6.1% | +9.6% |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |